GO
| HSI1 | 26,486.96 | +98.52 | 205.57B |
| HSCEI1 | 8,896.38 | +20.00 | 74.61B |
| Back Zoom + Zoom - Block Traded | |
|
BEONE MEDICINES' BEQALZI Receives US Approval for Treatment of Adult Lymphoma Patients
2026-05-14 09:09:43 BEONE MEDICINES (06160.HK) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI, a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition - with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. ~ AASTOCKS Financial News Website: www.aastocks.com | |